Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content
HomeCompareMounjaro vs Zepbound

Medication comparison

Mounjaro vs Zepbound

Medically reviewed by Dr. Jane Novak, MD, MPH 8 min read Fact checked Editorial integrityUpdated Jun 5, 2026

Mounjaro and Zepbound are both GIP/GLP-1 dual receptor agonist medications used for Type 2 diabetes and Chronic weight management. The table below compares FDA-approved indications, dosing, weight-loss outcomes, side effects, contraindications, and current pricing — all sourced from the manufacturer prescribing information.

Find a provider for Mounjaro or Zepbound →

Affiliate disclosure: we earn commission on signups. Editorial ranking stays independent.

This is general drug information, not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication.

Top 3 providers prescribing Mounjaro or Zepbound

Affiliate links — we earn commission on conversions; editorial ranking is independent.

Drug A

Mounjaro

tirzepatide

GIP/GLP-1 dual receptor agonist

Eli Lilly

See full overview

Drug B

Zepbound

tirzepatide

GIP/GLP-1 dual receptor agonist

Eli Lilly

See full overview

Overview

PropertyMounjaroZepbound
Generic nametirzepatidetirzepatide
Drug classGIP/GLP-1 dual receptor agonistGIP/GLP-1 dual receptor agonist
ManufacturerEli LillyEli Lilly
Brand namesMounjaroZepbound

Approved uses

PropertyMounjaroZepbound
Approved indicationsType 2 diabetesChronic weight management, Obstructive sleep apnea (adults with obesity)

Dosing

PropertyMounjaroZepbound
Typical dosingTitrate to 15 mg (weekly SC injection)Titrate to 15 mg (weekly SC injection)

Side effects & warnings

PropertyMounjaroZepbound
Top side effectsNausea (29.6%), Diarrhea (23%), Vomiting (12.6%)Nausea (29.6%), Diarrhea (23%), Vomiting (12.6%)
Contraindications——
Boxed warningYesYes

Special populations

PropertyMounjaroZepbound
PregnancyC — Discontinue at least 1 month before a planned pregnancy.C — Discontinue at least 1 month before a planned pregnancy.

Storage

PropertyMounjaroZepbound
StorageRefrigerate before first use. After first use, room temperature up to 21 days.Refrigerate before first use. After first use, room temperature up to 21 days.

Cost

PropertyMounjaroZepbound
Avg monthly cost$1023.04$1059.87

FDA boxed warning

Mounjaro: Risk of thyroid C-cell tumors. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Zepbound: Risk of thyroid C-cell tumors. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Already on Mounjaro and considering Zepbound?

Same drug (tirzepatide), Zepbound is the weight-loss-labeled version.

Read the switching guide

Frequently asked

What is the difference between Mounjaro and Zepbound?

Mounjaro is tirzepatide (GIP/GLP-1 dual receptor agonist) and Zepbound is tirzepatide (GIP/GLP-1 dual receptor agonist). Both contain the same active ingredient, dosed differently for different FDA-approved indications.

Is Mounjaro or Zepbound more effective for weight loss?

Mounjaro and Zepbound share the same active ingredient (tirzepatide). Average weight loss outcomes track the FDA-approved dose for each brand: STEP 1 reported 14.9% mean weight loss on the higher chronic-weight-management dose vs roughly half that on the lower diabetes-dose. The differentiator is dosing and indication, not molecule potency.

Can I switch between Mounjaro and Zepbound?

Yes — see our directional switching guide at /switching/mounjaro-to-zepbound for FDA-label dose conversion and what to expect during the transition.

Other GLP-1 head-to-head comparisons

Compare Mounjaro or Zepbound against another GLP-1

More medication context

Tools and guides that pair with this comparison.

Affiliate disclosure: we earn commissions when readers sign up through our links. Editorial ranking is independent.